The K-mRNA Consortium announced on Sept. 9 that Dong-A ST and Ecell have become members of the consortium launched in June this year. The members of the consortium for COVID-19 vaccine development also include Hanmi Pharmaceutical, GC Pharma, ST Pharm and the Korea Innovative Medicines Consortium.Do
Dong-A ST, a pharmaceutical affiliate of Dong-A Socio Group, has drastically revamped its R&D (R&D) organization. It created a biotech lab and introduced a team system to its new drug lab to speed up the pace of research."The reform is intended to expand the company’s research domain from synthetic
Daewoo Engineering & Construction (Daewoo E&C) announced on April 27 that it has signed a contract with the Land Transportation Authority (LTA) of Singapore to construct the CR108 section for the Cross Island subway line.It is a project to design and construct Pasir Ris Station, a transfer station o
Dong-A ST announced on March 12 that it has signed a contract with E& Investment, a Korean venture capital which owns a 33 percent stake in U.S. pharmaceutical company NeuroBo Pharmaceuticals, to be delegated its voting right to the U.S. company.Under the deal, Dong-A ST will secure managerial contr
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. We believe that Daewoong Pharm turned to OP q-q in 3Q20 thanks to reduced litigation costs. However, with ITC litigation risk yet to play out, we advise taking a conservative approach for now. Al
Dong-A ST announced on Sept. 22 that the U.S. Food and Drug Administration (FDA) has approved phase 2b/3a clinical trials for repositioning of its diabetes treatment Suganon (component name: Evogliptin) as a medication for calcific aortic valve disease (CAVD), which currently has no other remedy.The
Hyundai Engineering & Construction (E&C) has won a railway construction project in the Philippines.A consortium formed by Hyundai E&C will build the first section of the Malolos to Clark Railway for US$573 million. Hyundai E&C’s portion is US$330 million (57.5 percent). The company received a letter
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. While the majority of pharma plays have enjoyed share price expansion as of late on Covid-19 effects, earnings at CKD look to be justifying the firm’s valuations. Considering 2H20 R&D momentum, w
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Affected by administrative measures of the MFDS over March~May, Dong-A ST recorded a 2Q20 operating loss. Although cost reduction effects due to Covid-19 remain in play, if R&D costs increase, th
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Owing to the Covid-19 outbreak, all pharmas have enjoyed a reduction in marketing costs. But, this positive, along with strong product sales, has resulted in CKD displaying outstanding 2Q20 earni
A group of 10 Korean pharmaceutical and biotech companies have moved into the Cambridge Innovation Center (CIC) in Boston.According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the 10 companies share an office in the CIC in Boston. The 10 companies are Chong Kun Dang, Daewoo
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. CKD’s 1Q20 results topped consensus on steady sales growth for prescription drugs (led by treatments for chronic diseases) and reduced SG&A expenses.Needs R&D investments to bear fruitAlthough ad
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Dong-A ST delivered quarterly record-high earnings in 1Q20 on supply expansion prior to enforcement of the MFDS’s order to suspend business operations (March~May). But, operating losses in 2Q20 a
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Chong Kun Dang (CKD) should feel limited Covid-19 impacts, thanks to its chronic disease-oriented drug portfolio. While we expect CKD’s 1Q20 earnings to show improvement on SG&A expense reduction
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Dong-A ST’s 1Q20 earnings are expected to show y-y improvement, thanks to supply expansion prior to enforcement of the MFDS’s order to suspend business operations (March-May). However, we anticip
Dong-A ST Co. are stepping up efforts to develop new drugs. The company has developed four new homegrown treatments and has been investing 10 percent of its sales in research and development (R&D) every year to achieve its goal to become a leading company with globally sold new medicines.The company
Dong-A Socio Holdings chairman Kang Jeong-seok, who was put on trial for providing illegal rebates to doctors, was sentenced to prison in the second trial.The Busan High Court sentenced Kang to two and a half years in prison and 13 billion won in fines on charges of embezzling large amounts of compa
Chong Kun Dang Pharmaceutical Corp. (CKD) announced on Dec. 2 that it has recently received sales approval for its second-generation anemia biosimilar ”CKD-11101" from the Ministry of Food and Drug Safety of South Korea. CKD-11101 is the first biosimilar version of novel erythropoiesis stimulating p
Korean pharmaceutical and biotech companies have signed seven out-licensing contracts worth US$2.375 billion so far this year. This figure is nearly twice the figure of US$1.234 billion in eight deals. Industry analysts say that technology exports by Korean pharmaceutical and biotech industry are in
ST Pharm Co., a Korean pharmaceutical company. announced on Oct. 23 that its candidate for HIV treatment, "STP03-0404," has been selected as a life science project supported by the National Institute of Health (NIH) of the United States.ST Pharm Co. is an affiliate of Dong-A Socio Holdings, a holdin